Drug Type Monoclonal antibody |
Synonyms VVB 130:VEGFi, VVB130:VEGFi |
Target |
Action antagonists, inhibitors |
Mechanism IL6RB antagonists(Interleukin-6 receptor subunit beta antagonists), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Age Related Macular Degeneration | Preclinical | Singapore | 01 Dec 2025 | |
| Diabetic macular oedema | Preclinical | Singapore | 01 Dec 2025 | |
| Uveitis | Preclinical | Singapore | 01 Dec 2025 |






